MYGN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Myriad Genetics Inc (MYGN) is not a strong buy for a beginner, long-term investor at this time. While the company has reported some positive developments, including exceeding Q4 revenue expectations and launching new products in 2026, the financial performance shows significant declines in net income, EPS, and gross margin YoY. Additionally, analysts have lowered price targets, and technical indicators suggest a bearish trend. The absence of strong trading signals from Intellectia Proprietary Trading Signals further supports a cautious approach.
The MACD is positive and expanding, suggesting slight bullish momentum. However, the RSI is neutral, and the moving averages indicate a bearish trend (SMA_200 > SMA_20 > SMA_5). Key support is at $4.155, and resistance is at $5.385. The stock is trading pre-market at $4.87, near its pivot point of $4.77, but the overall trend remains weak.
Q4 2025 revenue exceeded expectations at $209.8 million.
14% YoY growth in MyRisk test results, indicating strong demand in oncology.
Launch of new products in 2026, including AI-enhanced Prolaris test and expanded MyRisk panel.
Significant YoY declines in net income (-81.41%), EPS (-82.98%), and gross margin (-2.34%).
Analysts have lowered price targets, citing limited visibility on growth and profitability improvements.
Stock trend analysis predicts a potential decline of -2.37% in the next day and -14.76% in the next month.
In Q4 2025, revenue dropped slightly by -0.38% YoY to $209.8 million. Net income fell sharply by -81.41% YoY to -$7.9 million, and EPS declined by -82.98% YoY to -$0.08. Gross margin decreased to 69.97%, down -2.34% YoY. Despite exceeding revenue expectations, the overall financial performance remains weak.
Analysts have lowered price targets across the board: UBS reduced the target to $6 from $8, Wells Fargo to $6 from $6.50, and TD Cowen to $7 from $9. All analysts maintain neutral or hold ratings, reflecting cautious sentiment due to limited visibility on growth and profitability improvements.
